Pilot Trial of N-acetylcysteine and Tigecycline as a Catheter-Lock Solution for Treatment of Hemodialysis Catheter–Associated Bacteremia

Abstract

We evaluated a catheter-lock solution consisting of N-acetylcysteine, tigecycline, and heparin for catheter salvage in patients with hemodialysis catheter-associated bacteremia. Eighteen case patients received the catheter-lock solution for 14 days plus systemic antibiotic therapy. Treatment was successful for 15 (83%) of the 18 case patients within 90 days of follow-up, with a median catheter retention interval of 64.5 days.Trial registration. ClinicalTrials.gov identifier: NCT00614679.